Corvus Pharmaceuticals Advances Soquelitinib to Phase 3 for Peripheral T-Cell Lymphoma While Expanding Atopic Dermatitis Trial
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) announced on October 10 2024 that it has launched a registrational Phase 3 st...
Read story →